Thomas E Delea

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Topics

Combination Therapy

Multiple Myeloma

Metastatic Renal Cell Carcinoma

Top Venues

Oncology and therapy

PharmacoEconomics

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas E Delea, Qiufei Ma, Glenn S Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncology and therapy 12 (3) (2024)
Thomas E Delea, Qiufei Ma, Glenn S Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncology and therapy (2024)
Thomas E Delea, Qiufei Ma, Glenn S Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncology and therapy 12 (3) (2024)
Thomas E Delea, Qiufei Ma, Glenn S Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population. Oncology and therapy 12 (3) (2024)
Caitlin Eichten, Qiufei Ma, Thomas E Delea, May Hagiwara, Roberto Ramos, Şerban R Iorga, Jie Zhang, Richard T Maziarz
Lifetime Costs for Treated Follicular Lymphoma Patients in the US. PharmacoEconomics 39 (10) (2021)
Daniel Stellato, Marroon E Thabane, David Chandiwana, Jinhee Park, Thomas E Delea
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective. PharmacoEconomics 39 (7) (2021)
Daniel Stellato, Marroon E Thabane, Jinhee Park, David Chandiwana, Thomas E Delea
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective. PharmacoEconomics 39 (9) (2021)
Thomas E Delea, Xinke Zhang, Jordan Amdahl, Diana Boyko, Franziska Dirnberger, Marco Campioni, Ze Cong
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. PharmacoEconomics 37 (9) (2020)
Deepu Madduri, May Hagiwara, Kejal Parikh, Corey Pelletier, Thomas E Delea, Arianna Kee, Ajai Chari
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future oncology (London, England) 17 (5) (2020)
Jordan Amdahl, Jose Diaz, Arati Sharma, Jinhee Park, David Chandiwana, Thomas E Delea
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PloS one 12 (6) (2017)
Thomas E Delea, Derek Weycker, Mark Atwood, Dion Neame, Fabián P Alvarez, Evelyn Forget, Joanne M Langley, Ayman Chit
Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PloS one 12 (5) (2017)